- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03449784
Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias (OBDYSLIP)
Observatory of Patients With Dyslipidemia Hospitalized in Endocrinology-Diabetology-Nutrition Unit: Observational Study
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years in Europe, and is also increasingly common in developing countries. In the European Union, the economic cost of CVD represents annually €192 billion in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. LDL-cholesterol (LDL-C) is one of the major risk factors for CVD, through its role in the development of atherosclerosis. The efficacy of statins has been demonstrated by a considerable amount of literature not only in lowering LDL cholesterol levels but also in reducing cardiovascular events, both in diabetes and non-diabetes patients. Guidelines for the management of dyslipidemia have emerged from different countries. Thereby, in 2016 the French Society of Endocrinology (SFE) and the New French Society of Atherosclerosis (NSFA) published a consensus statement on the management of dyslipidemias integrating features from European recommendations and in 2017 the Haute Autorité de Santé updated the French guidelines. However, LDL-C goal attainment has rarely been assessed specifically in diabetes population, in which CVD is of particular importance. This study aimed to assess the rate of dyslipidaemias in a population of patient hospitalized in Endocrinology-Diabetology-Nutrition unit.
This observational study was carried in the Diabetes-Nutrition unit of the University Hospital of Montpellier - France. All consecutive patients admitted to that unit during the study period were assessed for eligibility. Data on age, sex, tobacco smoking, body mass index, hypertension (treatment of previously diagnosed hypertension or blood values > 140/90 mmHg), presence and type of CVD (coronary artery disease, stroke and transient ischemic attack, peripheral arterial disease), were collected at admission. LDL-C, HDL-C and triglycerides levels calculated with the Friedewald formula, and glomerular filtration rate calculated according to the CKD-EPI formula were obtained from blood samples taken within 24 hours of hospitalization admission. Information on the name and daily dose of lipid lowering drugs (statins, fibrate, ezetimibe …) at admission was documented. Cardiovascular risk level and LDL-C target values were defined according to 2011 and 2016 ESC guidelines and 2017 French guidelines.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Montpellier, France, 34295
- Recruiting
- UHMontpellier
-
Principal Investigator:
- P Goudry
-
Principal Investigator:
- A Avignon
-
Principal Investigator:
- A Sultan
-
Principal Investigator:
- P Cestac
-
Principal Investigator:
- B Sallerin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria:
- Patients aged above 18 years old, admitted to the department during the study period and hospitalized for at least 24 hours, blood samples taken within 24 hours of hospitalization admission (LDL-C, triglycerides)
Exclusion criteria:
- Patients with elevated triglycerides (>4.5 mmol/L or >400 mg/dL)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
patients with dyslipidemia non achieving LDL-C target
|
Detection of patients with dyslipidemia
|
patients with dyslipidemia achieving LDL-C target
|
Detection of patients with dyslipidemia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number with dyslipidemia
Time Frame: 1 day
|
number of patient with dyslipidemia
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of patient not achieving LDL-C target according to cardiovascular risk
Time Frame: 1 day
|
number of patient not achieving LDL-C target according to cardiovascular risk
|
1 day
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Cyril BREUKER, University Hospital, Montpellier
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL18_0104
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Patient With Dyslipidemia
-
National Taiwan University HospitalUnknownPatient With Invasive Cervical Carcinoma | Patient With CIN Lesion | Patient With HPV Infected Patients Without Histopathologic Lesion | Normal Populations.Taiwan
-
Peking Union Medical College HospitalCompletedPatient After Cardiac Valve Surgery | Patient With Prolonged Mechanical VentilationChina
-
Centre Hospitalier Universitaire DijonTerminatedPatient With Bronchial EndoscopyFrance
-
Hospital Universitario Reina Sofia de CordobaSpanish Society of Family and Community MedicineCompletedPatients With DyslipidemiaSpain
-
AstraZenecaCompletedPatients With DyslipidemiaBrazil
-
Tel-Aviv Sourasky Medical CenterCompleted
-
Chong Kun Dang PharmaceuticalCompletedHypertensive Patients With DyslipidemiaKorea, Republic of
-
Suzhou Genhouse Bio Co., Ltd.Not yet recruitingPatient With Advanced Solid TumorChina
-
Edwards LifesciencesCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedPatient Mechanically Ventilated With APRV ModeFrance
Clinical Trials on Detection of patients with dyslipidemia
-
Peking University Third HospitalPeking University First Hospital; Wuhan Asia Heart HospitalCompletedCoronary Heart Disease
-
Instituto de Investigación Biomédica de SalamancaCarlos III Health InstituteRecruitingCutaneous T-Cell LymphomaSpain
-
Norman A. ParadisUnited States Department of Defense; Dartmouth College; University of Maryland...Not yet recruitingHemorrhage | Occult BleedingUnited States
-
ANRS, Emerging Infectious DiseasesEPISTEMCompleted
-
University of SevilleInstituto Hispalense de Pediatría, Seville, SpainCompleted
-
Institut de Sante Parasport Connecte SynergiesAssistance Publique - Hôpitaux de ParisRecruitingDisability or Chronic Disease Leading to DisablementFrance
-
National Taiwan University HospitalNot yet recruitingEducation, MedicalTaiwan
-
Rennes University HospitalCompletedRenal Insufficiency, Chronic | Organ GraftFrance
-
Hamid Al-Essa Organ Transplant CenterCompletedCOVID-19 Positive Patients With Acute Kidney InjuryKuwait
-
Prince of Songkla UniversityCompletedGastroesophageal Reflux DiseaseThailand